Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

類似資料

• CLINICAL ACTIVITY OF SEQUENTIAL FLAVOPIRIDOL, CYTOSINE ARABINOSIDE, AND MITOXANTRONE FOR ADULTS WITH NEWLY DIAGNOSED, POOR RISK ACUTE MYELOGENOUS LEUKEMIA
  著者:: Karp, Judith E., 等
  出版事項: (2009)
• Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
  著者:: Karp, Judith E., 等
  出版事項: (2011)
• Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature
  著者:: Norsworthy, Kelly J., 等
  出版事項: (2017)
• Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
  著者:: Karp, Judith E., 等
  出版事項: (2012)
• The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.
  著者:: Slevin, M L, 等
  出版事項: (1981)